Lyndah Dreiling

Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial

Andrew D. Zelenetz, Jacqueline C. Barrientos, Jennifer R Brown et al. · The Lancet Oncology · 2017 · 247 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial

Jeffrey A. Jones, Tadeusz Robak, Jennifer R. Brown et al. · The Lancet Haematology · 2017 · 198 citations

Medicine, Oncology, Pharmacology +10

Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL

Paul M. Barr, Gene Saylors, Stephen E. Spurgeon et al. · Blood · 2016 · 142 citations

Medicine, Pharmacology, Pharmacotherapy +7

Elderly Cancer Patients Receiving Chemotherapy Benefit from First-Cycle Pegfilgrastim

Lodovico Balducci, Hafez Al-Halawani, Veena Charu et al. · The Oncologist · 2007 · 130 citations · Full text

Pharmacy, Geriatric Medicine, Geriatric Oncology Pharmacotherapy +11

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non–Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies

Howard A. Burris, Chandra P. Belani, Peter A. Kaufman et al. · Journal of Oncology Practice · 2010 · 101 citations

Medicine, Oncology, Pharmacology +17